InsiderTrades.com logo

PTN Insider Trading

Insider Ownership Percentage: 7.10%
Insider Buying (Last 12 Months): $12,720.00
Insider Selling (Last 12 Months): $31,698.34

Palatin Technologies Insider Trading History Chart

This chart shows the insider buying and selling history at Palatin Technologies by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Palatin Technologies Share Price & Price History

Current Price: $0.95
Price Change: ▲ Price Increase of +0.0049 (0.52%)
As of 01/24/2025 05:10 PM ET

This chart shows the closing price history over time for PTN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Palatin Technologies Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/1/2024Stephen T WillsCFOSell4,999$1.66$8,298.34235,456View SEC Filing Icon  
4/11/2024Robert K Deveer JrDirectorBuy6,000$2.12$12,720.0040,845View SEC Filing Icon  
3/6/2024Robert K Deveer JrDirectorSell11,700$2.00$23,400.0034,845View SEC Filing Icon  
12/6/2023Stephen T WillsCFOSell4,998$2.51$12,544.98327,522View SEC Filing Icon  
12/4/2023Alan W DuntonDirectorSell200$2.48$496.0045,074View SEC Filing Icon  
12/21/2022Alan W DuntonDirectorSell200$2.97$594.0041,420View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Palatin Technologies (NYSEAMERICAN:PTN)

11.50% of Palatin Technologies stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at PTN by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Palatin Technologies Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
1/15/2025HB Wealth Management LLC110,500$0.13M0.0%+86.3%0.565%Search for SEC Filing on Google Icon
11/20/2024Virtu Financial LLC57,520$51K0.0%N/A0.294%Search for SEC Filing on Google Icon
11/15/2024XTX Topco Ltd29,063$26K0.0%+98.6%0.149%Search for SEC Filing on Google Icon
8/15/2024Armistice Capital LLC1,678,101$3.27M0.0%N/A8.663%Search for SEC Filing on Google Icon
8/12/2024XTX Topco Ltd14,631$29K0.0%N/A0.076%Search for SEC Filing on Google Icon
2/13/2024Armistice Capital LLC590,000$2.35M0.0%N/A4.294%Search for SEC Filing on Google Icon
5/11/2023Montis Financial LLC20,964$58K0.0%N/A0.188%Search for SEC Filing on Google Icon
10/27/2022US Bancorp DE6,269$37K0.0%-96.0%0.067%Search for SEC Filing on Google Icon
4/12/2022Connective Portfolio Management LLC50,000$1.42M3.0%N/A0.022%Search for SEC Filing on Google Icon
2/10/2022Qube Research & Technologies Ltd57,164$29K0.0%N/A0.025%Search for SEC Filing on Google Icon
2/10/2022WINTON GROUP Ltd371,134$0.19M0.0%-52.4%0.160%Search for SEC Filing on Google Icon
2/1/2022Qube Research & Technologies Ltd57,164$29K0.0%N/A0.025%Search for SEC Filing on Google Icon
1/31/2022Commonwealth Equity Services LLC119,745$61K0.0%+104.1%0.052%Search for SEC Filing on Google Icon
11/5/2021Advisory Services Network LLC62,700$28K0.0%N/A0.027%Search for SEC Filing on Google Icon
10/28/2021WINTON GROUP Ltd780,370$0.35M0.0%-12.4%0.337%Search for SEC Filing on Google Icon
8/17/2021Bridgeway Capital Management LLC1,054,100$0.64M0.0%-15.6%0.458%Search for SEC Filing on Google Icon
8/16/2021State Street Corp700,015$0.43M0.0%+902.6%0.304%Search for SEC Filing on Google Icon
8/11/2021BlackRock Inc.3,133,412$1.91M0.0%-16.2%1.362%Search for SEC Filing on Google Icon
8/10/2021WINTON GROUP Ltd890,900$0.54M0.0%-3.1%0.387%Search for SEC Filing on Google Icon
8/5/2021GSA Capital Partners LLP1,096,491$0.67M0.1%+1,781.1%0.477%Search for SEC Filing on Google Icon
5/19/2021Virtu Financial LLC63,800$44K0.0%-82.9%0.028%Search for SEC Filing on Google Icon
5/13/2021Bank of New York Mellon Corp101,252$70K0.0%-28.4%0.044%Search for SEC Filing on Google Icon
5/12/2021Geode Capital Management LLC1,651,856$1.14M0.0%+5.1%0.718%Search for SEC Filing on Google Icon
5/12/2021CIBC Private Wealth Group LLC57,000$39K0.0%N/A0.025%Search for SEC Filing on Google Icon
5/12/2021UBS Group AG38,421$26K0.0%+482.6%0.017%Search for SEC Filing on Google Icon
5/11/2021Acadian Asset Management LLC2,363,634$1.63M0.0%-55.8%1.027%Search for SEC Filing on Google Icon
5/10/2021GSA Capital Partners LLP58,290$40K0.0%N/A0.025%Search for SEC Filing on Google Icon
4/26/2021GWM Advisors LLC130,000$90K0.0%+30.0%0.057%Search for SEC Filing on Google Icon
4/22/2021James Investment Research Inc.130,000$90K0.0%+30.0%0.057%Search for SEC Filing on Google Icon
2/24/2021Virtu Financial LLC372,539$0.25M0.0%N/A0.162%Search for SEC Filing on Google Icon
2/10/2021Renaissance Technologies LLC65,600$44K0.0%N/A0.029%Search for SEC Filing on Google Icon
2/9/2021Wells Fargo & Company MN145,605$99K0.0%-57.8%0.063%Search for SEC Filing on Google Icon
2/2/2021First Trust Advisors LP511,721$0.35M0.0%-4.1%0.223%Search for SEC Filing on Google Icon
1/1/2021Sei Investments Co.245,033$0.12M0.0%+149.1%0.107%Search for SEC Filing on Google Icon
11/13/2020Morgan Stanley121,138$58K0.0%-43.8%0.053%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Palatin Technologies logo
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.
Read More on Palatin Technologies

Today's Range

Now: $0.95
Low: $0.90
High: $0.99

50 Day Range

MA: N/A

52 Week Range

Now: $0.95
Low: $0.68
High: $5.65

Volume

286,390 shs

Average Volume

328,001 shs

Market Capitalization

$18.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.9

Who are the company insiders with the largest holdings of Palatin Technologies?

Palatin Technologies' top insider shareholders include:
  1. Stephen T Wills (CFO)
  2. Alan W Dunton (Director)
  3. Robert K Deveer Jr (Director)
Learn More about top insider investors at Palatin Technologies.

Who are the major institutional investors of Palatin Technologies?

Palatin Technologies' top institutional shareholders include:
  1. HB Wealth Management LLC — 0.57%
Learn More about top institutional investors of Palatin Technologies stock.

Which institutional investors are buying Palatin Technologies stock?

During the previous quarter, PTN stock was acquired by institutional investors including:
  1. HB Wealth Management LLC